Table 1.
Patient characteristics.
| ID | Age | Sex | PS ECOG | Primary tumor location | Metastatic sites | KRAS | I Line CT | Best response | PFS (months) |
|---|---|---|---|---|---|---|---|---|---|
| COL001 | 67 | M | 0 | Transverse colon | Liver, peritoneum | pG12D | FOLFOX bevacizumab | SD | 10.0 |
| COL003 | 76 | F | 0 | Left colon/rectum | Liver, peritoneum | pG12A | FOLFOX bevacizumab | PR | 8.0 |
| COL004 | 84 | M | 1 | Left colon/rectum | Liver | pG12D | 5-FU | SD | 8.2 |
| COL005 | 61 | M | 0 | Left colon/rectum | Liver, lung, lymph nodes | pG13D | FOLFOX bevacizumab | PD | 3.8 |
| COL006 | 75 | M | 0 | Left colon/rectum | Lung, local recurrence | pG12C | FOLFOX bevacizumab | PR | 10.0 |
| COL007 | 53 | F | 0 | Left colon/rectum | Liver, lung, lymph nodes | pG12S | FOLFOXIRI bevacizumab | PR | 12.2 |
| COL012 | 60 | F | 0 | Rigt colon | Liver | pG12A | FOLFOX bevacizumab | PR | 7.0 |
| COL015 | 62 | F | 0 | Rigt colon | Liver | pG13V | FOLFOX | CR | 15.6 |
| COL017 | 78 | M | 0 | Rigt colon | Liver | pA146K | FOLFOX bevacizumab | PR | 9.1 |
Abbreviations: CR: complete response; CT: chemotherapy; FOLFOX: 5-fluorouracil, oxaliplatin; FOLFOXIRI: 5-fluorouracil, oxaliplatin, irinotecan; PD: progressive disease; PFS: progression-free survival; PR: partial response; SD: stable disease; 5-FU: 5-fluorouracil.